A recent study reported that, in ALK mutant, MYCN amplified neuroblastomas, resistance to ALK inhibitors is accompanied by a decrease in MYCN expression and upregulation of the brother of the regulator of imprinted sites (BORIS) protein. Here, MYCN is linked to neuroblastoma.